Metformin inhibits growth and sensitizes osteosarcoma cell lines to cisplatin through cell cycle modulation

Oncology Reports

Volumn 31, Issue 1, 2014, Pages 370-375

  Quattrini, Irene ^a   Conti, Amalia ^a   Pazzaglia, Laura ^a   Novello, Chiara ^a   Ferrari, Stefano ^a   Picci, Piero ^a   Benassi, Maria Serena ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Cell cycle; Cisplatin; Metformin; Osteosarcoma; Protein expression

Indexed keywords

ADENYLATE KINASE; ADENYLATE KINASE ALPHA; CHECKPOINT KINASE 1; CISPLATIN; CYCLIN A; CYCLIN D1; CYCLIN E; LIPOCORTIN 5; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR BETA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ASSAY; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE REGULATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; CYCLIN D1; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; OSTEOSARCOMA; PROTEIN KINASES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84891956900     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2862     Document Type: Article

References (38)

1. Picci P, Mercuri M, Ferrari S, Alberghini M, Briccoli A, Ferrari C, Pignotti E and Bacci G: Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. Ann Oncol 21: 1366-1373, 2010.
2. Hattinger CM, Pasello M, Ferrari S, Picci P and Serra M: Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs 15: 615-634, 2010.
3. Liotta LA and Petricoin E: Cancer biomarkers: closer to delivering on their promise. Cancer Cell 20: 279-280, 2011.
4. Stumvoll M, Nurjhan N, Perriello G, Dailey G and Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333: 550-554, 1995.
5. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ and Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174, 2001.
6. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305, 2005.
7. Bowker SL, Majumdar SR, Veugelers P and Johnson JA: Increased cancer related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29: 254-258, 2006.
8. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y and Bost F: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27: 3576-3586, 2008.
9. Hawley SA, Gadalla AE, Olsen GS and Hardie DG: The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51: 2420-2425, 2002.
10. Towler MC and Hardie DG: AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100: 328-341, 2007.
11. Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WG IV, Schlattner U, Neumann D, Brownlee M, Freeman MB and Goldman MH: Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem 279: 43940-43951, 2004.
12. Dowling RJ, Goodwin PJ and Stambolic V: Understanding the benefit of metformin use in cancer treatment. BMC Med 6: 33, 2003.
13. Kahn BB, Alquier T, Carling D and Hardie DG: AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15-25, 2005.
14. Carling D: The AMP-activated protein kinase cascade - a unifying system for energy control. Trends Biochem Sci 29: 18-24, 2004.
15. Stein SC, Woods A, Jones NA, Davison MD and Carling D: The regulation of AMP-activated protein kinase by phosphorylation. Biochem J 345: 437-443, 2000.
16. Yun H, Lee M, Kim SS and Joohun HA: Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma. Biol Chem 280: 9963-9972, 2005.
17. Neurath KM, Keough MP, Mikkelsen T and Claffey KP: AMP-dependent protein kinase alpha 2 isoform promotes hypoxia-induced VEGF expression in human glioblastoma. Glia 53: 733-743, 2006.
18. Lee M, Hwang JT, Lee HJ, Kang I, Kim SS and Ha J: AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic conditions in DU145 cells. J Biol Chem 278: 39653-39661, 2003.
19. Ouchi N, Shibata R and Walsh K: AMP-activated protein kinase signaling stimulates VEGF expression and angiogenesis in skeletal muscle. Circ Res 96: 838-846, 2005.
20. Nagata D, Mogi M and Walsh K: AMP-activated protein kinase (AMPK) signalling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J Biol Chem 278: 31000-31006, 2003.
21. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B and Thompson CB: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67: 6745-6752, 2007.
22. Phoenix KN, Vumbaca F and Claffey KP: Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 113: 101-111, 2009.
23. Zakikhani M, Dowling R, Fantus IG, Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10269-10273, 2006.
24. Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H, Nakajima N, Nagashima Y, Wada K, Nakagama H and Nakajima A: Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci 99: 2136-2141, 2008.
25. Luo Q, Hu D, Hu S, Yan M, Sun Z and Chen F: In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma. BMC Cancer 12: 517, 2012.
26. Novello C, Pazzaglia L, Cingolani C, Conti A, Quattrini I, Manara MC, Tognon M, Picci P and Benassi MS: miRNA expression profile in human osteosarcoma: Role of miR-1 and miR-133b in proliferation and cell cycle control. Int J Oncol 42: 667-675, 2013.
27. Hidalgo M and Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19: 6680-6686, 2000.
28. Collins I and Garrett MD: Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol 5: 366-373, 2005.
29. Merry C, Fu K, Wang J, Merry C, Fu K and Wang J: Targeting the checkpoint kinase Chk1 in cancer therapy. Cell Cycle 9: 279-283, 2010.
30. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE and Thor AD: Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8: 909-915, 2009.
31. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO and de Vries EG: Metformin: taking away the candy for cancer? Eur J Cancer 46: 2369-2380, 2010.
32. Montanini L, Lasagna L, Barili V, Jonstrup SP, Murgia A, Pazzaglia L, Conti A, Novello C, Kjems J, Perris R and Benassi MS: MicroRNA cloning and sequencing in osteosarcoma cell lines: differential role of miR-93. Cell Oncol 35: 29-41, 2012.
33. Rocha GZ, Dias MM, Ropelle ER, Osório-Costa F, Rossato FA, Vercesi AE, Saad MJ and Carvalheira JB: Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res 17: 3993-4005, 2011.
34. Motoshima H, Goldstein BJ, Igata M and Araki E: AMPK and cell proliferation - AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 574: 63-71, 2006.
35. Cip1. J Mol Signal 3: 18, 2008.
36. Eastman A: Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J Cell Biochem 91: 223-231, 2004.
37. Tu YS, Kang XL, Zhou JG, Lv XF, Tang YB and Guan YY: Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells. Eur J Pharmacol 670: 356-364, 2011.
38. Zhao H, Watkins JI and Worms H: Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci USA 99: 14795-14800, 2002.